Issue Date: June 30, 2008
Novartis Extends TB Drug Alliance
The Novartis Institute for Tropical Diseases, in Singapore, will collaborate with the Global Alliance for TB Drug Development for another five years. The partners hope to develop drug regimens that work faster against all forms of tuberculosis, including drug-resistant TB, and are safe to use in HIV-infected patients. NITD's work with the TB Alliance over the past four years has included the development of nitroimidazopyrans. In 2002, the TB Alliance licensed the nitroimidazole . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society